GeoVax receives patent allowance notice for DNA/MVA vaccine for HIV/AIDS
The patent, which is called "Compositions and Methods for Generating an Immune Response," is licensed exclusively from Emory University and the U.S. government and covers the uses, compositions and methods of GeoVax's DNA/MVA vaccine in the specific area of eliciting cellular and humoral immune responses to an HIV antigen.
"This patent is key to the commercialization of our DNA/MVA HIV vaccine technology," Robert T. McNally, the president and CEO of GeoVax, said. "We are pleased that the USPTO has confirmed that the claims in our patent application are patentable over the prior art of record."
The patent covers advances in DNA construct portion of GeoVax's vaccine, which forms the priming vaccine in the GeoVax HIV vaccine regimen.
In preclinical studies, the simian analogs of GeoVax's DNA/MVA vaccine were shown to provide up to 78 percent per exposure protection against SIV251, a highly virulent strain of simian immunodeficiency virus.
The GeoVax DNA/MVA vaccine is currently in a Phase I trial sponsored by the HIV Vaccine Trials Network. A Phase 2 trialis planned for 2014.